<DOC>
	<DOC>NCT00712322</DOC>
	<brief_summary>This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity. The results will support a benefit-risk based dosage recommendation for phase IIIa clinical trials.</brief_summary>
	<brief_title>2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description />
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Male and female patients ages 215 years Documented detrusor overactivity associated with a known neurological condition such as meningomyelocele or spinal cord injury, and confirmed by urodynamics at baseline Using clean intermittent catheterization (CIC) on a regular basis Participating in a bowel program on a regular basis Able to swallow the study medication in accordance to the protocol Patients and/or parent/guardian able to complete the bladder diary and follow the study procedures Treatment with drugs known to significantly affect the urinary bladder and urinary bladder outlet function Fecal impaction. Patients may be included, once this condition has resolved Clinically significant anatomical abnormalities or acquired disorders of the urinary tract Previous reconstructive surgery (augmentation etc.) of the bladder or bladder outlet Symptomatic urinary tract infection unresolved at time of urodynamic study and/or completion of bladder diary. Diabetes insipidus Electro stimulation therapy or bladder training within 2 weeks prior to Visit 1 and at any time during the study Concomitant diseases, in which the use of darifenacin is contraindicated History of hypersensitivity to darifenacin or to drugs with similar chemical structures Patients with any physical and cognitive impairment or any other condition which in the opinion of the investigator makes the patient unsuitable for inclusion Female adolescent of childbearing potential, unless using an acceptable method of contraception Pregnant or nursing (lactating) female adolescents Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Pediatric, Children, Urodynamics, Oral Suspension, Overactive bladder, Dose-finding, Neurogenic Detrusor Overactivity, Meningomyelocele, Spinal cord injury</keyword>
</DOC>